Lucence retweeted
Besides the regular @ASCO #ASCO23 program, there are a number of interesting sponsored presentations.
Join me for dinner & discussion about #ctRNA being a game changer for #lungcancer detection and treatment selection #liquidbiopsy.
June 3 - 6:30pm CT, hosted by @lucencehealth bit.ly/lucence-asco23-dinner
@SylvesterCancer @ChristianRolfo @JackWestMD @n8pennell @NarjustFlorezMD @SamuelKareffMD @PriscilaBCMD @Latinamd @MudadRaja
Lucence retweeted
Replying to @YawBediako_
@YawBediako_ Founder and CEO Yemaachi and among @NewAfricanMag's 100 Most Influential Africans, is on a mission to fix unequal healthcare for patients with African ancestry. Such a moment for this genomics partnership born out of our work together at @VAInstitute !
Lucence retweeted
proud to be on the scientific board for @LucenceHealth - we have three posters on our liquid biopsy platform @asco #asco22 @minhantan
Lucence retweeted
Thank you, @LucenceHealth, for supporting Conquer Cancer! Make sure to visit #ASCO22 booth 16112 where health care practitioners can choose a charity to a receive a $50 donation from Lucence when they provide their email address.
Lucence retweeted
Lucence Publishes Clinical Validation of LiquidHallmark Circulating Tumor DNA Test, Expands to RNA. The firm plans to ramp up US commercialization following the study, while continuing to develop its cell-free RNA diagnostic platform. ow.ly/Tztv103FzBl
Lucence retweeted
This is the first step in our journey to diversify precision oncology, shedding much needed light on cancer among people of African descent: businesswire.com/news/home/2…
Lucence retweeted
Collaboration with @LucenceHealth to evaluate a sensitive ctDNA platform-co-led by Dr Praful Ravi @DanaFarber_GU- BRCA and PIK3CA mutations may be candidates for resistance to #immune checkpoint inhibitors in metastatic #urothelialcarcinoma
#ESMO21: Dana-Farber's Guru Sonpavde, MD (@sonpavde), details a study looking at circulating tumor DNA alterations to identify resistance mechanisms to immune checkpoint inhibitors in metastatic urothelial #carcinoma
👉 Abstract 709P: ms.spr.ly/6015XpYqL cc @DanaFarber_GU
Lucence retweeted
Exciting collaboration of @DanaFarber_GU with @LucenceHealth-presentation #ESMO2021-sensitive ctDNA platform sheds insights on #bladdercancer biology-PI3K and BRCA alterations appear to be resistance mechanisms in selected metastatic patients on #immune checkpoint inhibitors
Lucence at #ESMO2021
Lucence is delighted to present new data from a study in collaboration with @DanaFarber showing the utility of liquid biopsy in late-stage bladder cancer.
Read our press release bwnews.pr/2XevFWi
Read our abstract https://nitter.gq/t.co/HjVch6veX1
Lucence retweeted
With CLIA licensing of our Palo Alto laboratory, Lucence can now offer US cancer patients our ultrasensitive liquid biopsy test LiquidHALLMARK with much faster turnaround times.
Read more here: bwnews.pr/3m3euxe
Lucence retweeted
Lucence Obtains CLIA Certification for Palo Alto Lab
@LucenceDx
360dx.com/liquid-biopsy/luce…
Lucence retweeted
Toward a SAFER World - SAFER Technology suite for COVID-19 mass-testing
✅Solve unlinked cases in days not weeks for community control - DeepMark™
Lucence retweeted
Toward a SAFER World - SAFER technology suite for COVID-19 mass-testing
✅Detect 36% more COVID-19 infections with saliva over swabs - SAFER™
✅Reduce vibration-arm syndrome and hands-on time for saliva processing by 83% - Starlight™
youtu.be/1cvAqEC6V5o
Lucence retweeted
Thank you #SingaporeSocietyofOncology @LucenceDx Tan Min Han, Rajesh Shah and Toh Chee Keong for a great discussion on #COVID19nCancer #LCSM #CCC19 @COVID19nCCC
Join @COVID19nCCC member @GlopesMd & a panel of experts for a conversation on #COVID19 & #lungcancer tomorrow at 8 PM ET/5 PM PT, hosted by the Singapore Society of Oncology. Register here: https://nitter.gq/t.co/XunRg67r0V #LCSM
Lucence retweeted
Very happy to see friends and colleagues from Asia and around the world joining us for this event. #Covid19nCancer #ccc19 @COVID19nCCC – at Miami, FL
Join @COVID19nCCC member @GlopesMd & a panel of experts for a conversation on #COVID19 & #lungcancer tomorrow at 8 PM ET/5 PM PT, hosted by the Singapore Society of Oncology. Register here: https://nitter.gq/t.co/XunRg67r0V #LCSM
Lucence retweeted
Association of the Coronavirus Disease 2019 (COVID-19) Outbreak With Enrollment in Cancer Clinical Trials [Jun 1, 2020] @junger47 et al. @JAMANetworkOpen ow.ly/hIo030qLGjq #COVID19ClinicalTrials #CCC19 #COVID19nCancer #2019nCoV #COVID19 @COVID19nCCC
Lucence retweeted
In the near term, the Singapore-based firm will focus on launching a laboratory-developed test version of its LiquidHallmark late-stage lung cancer treatment selection assay @LucenceDx #cancer
https://nitter.gq/t.co/OVxOQyvk70
Lucence retweeted
Our study is out! #CCC19 @asco #asco20 #covid19ncancer @oncoalert @totalhealthconf @sylvestercancer is proud to be one of the five founding institutions - A big thank you to all participants. This was a grassroots, crowdsourcing effort nobody could do alone @thelancet
Lucence retweeted
#ASCO20 Tip: It's a good idea to log in today or tomorrow to make sure you can log in successfully to the @ASCO website, and see the Virtual Program. #ASCO20 begins Friday May 29, 8 am Eastern Time (rise and shine, those of you on the West Coast).
meetings.asco.org/am/virtual…
Lucence retweeted
We need to learn/borrow/emulate everything we can from the countries that are winning on the fight against #COVID19.
There are some gems in here from @hsuliyang and @minhantan on how Singapore has been responding.
statnews.com/2020/03/23/sing…
























